908 Devices (MASS) Projected to Post Earnings on Wednesday

Key Points

• 908 Devices (NASDAQ:MASS) will report Q1 2026 results before the market opens on May 6 with analysts forecasting EPS of ($0.15) and revenue of $13.162 million, and a conference call scheduled for 8:30 AM ET.
• In the prior quarter (reported Mar. 3) the company beat estimates with EPS of ($0.05) vs. ($0.06) expected and revenue of $17.38 million, while analysts forecast $0 EPS for the current and next fiscal year and a consensus price target of $12.00.
• There has been notable insider selling (74,480 shares sold in the past 90 days) even as institutional ownership is high at 88.06%; the stock trades around $6.70 with a market cap of about $250.7 million and a 12‑month range of $4.20–$9.34.

908 Devices (NASDAQ:MASS - Get Free Report) is expected to post its Q1 2026 results before the market opens on Wednesday, May 6th. Analysts expect 908 Devices to post earnings of ($0.15) per share and revenue of $13.1620 million for the quarter. Individuals can find conference call details on the company's upcoming Q1 2026 earning report page for the latest details on the call scheduled for Wednesday, May 6, 2026 at 8:30 AM ET.

908 Devices (NASDAQ:MASS - Get Free Report) last posted its earnings results on Tuesday, March 3rd. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.01. 908 Devices had a net margin of 34.68% and a negative return on equity of 14.99%. The business had revenue of $17.38 million for the quarter, compared to analysts' expectations of $16.19 million. On average, analysts expect 908 Devices to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

908 Devices Price Performance

Shares of NASDAQ:MASS traded up $0.15 during trading on Tuesday, hitting $6.70. The company's stock had a trading volume of 131,192 shares, compared to its average volume of 292,850. The company has a 50-day moving average of $6.60 and a 200-day moving average of $6.51. 908 Devices has a 12 month low of $4.20 and a 12 month high of $9.34. The firm has a market cap of $250.73 million, a price-to-earnings ratio of 12.17 and a beta of 0.57.

Insider Activity at 908 Devices

In other 908 Devices news, SVP Kevin J. Mccallion sold 18,580 shares of 908 Devices stock in a transaction on Wednesday, April 8th. The shares were sold at an average price of $7.05, for a total transaction of $130,989.00. Following the completion of the transaction, the senior vice president directly owned 44,925 shares of the company's stock, valued at $316,721.25. The trade was a 29.26% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP John Kenneweg sold 7,787 shares of 908 Devices stock in a transaction on Friday, May 1st. The stock was sold at an average price of $6.83, for a total transaction of $53,185.21. Following the transaction, the senior vice president directly owned 76,039 shares of the company's stock, valued at $519,346.37. The trade was a 9.29% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 74,480 shares of company stock valued at $523,432. 23.70% of the stock is owned by corporate insiders.

Institutional Trading of 908 Devices

Institutional investors and hedge funds have recently made changes to their positions in the business. Raymond James Financial Inc. bought a new stake in shares of 908 Devices in the second quarter valued at about $48,000. Daiwa Securities Group Inc. bought a new position in 908 Devices in the second quarter worth about $61,000. Russell Investments Group Ltd. bought a new position in 908 Devices in the third quarter worth about $93,000. The Manufacturers Life Insurance Company bought a new position in 908 Devices in the second quarter worth about $77,000. Finally, Walleye Capital LLC bought a new position in 908 Devices in the second quarter worth about $82,000. 88.06% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

MASS has been the subject of a number of research analyst reports. Weiss Ratings raised shares of 908 Devices from a "sell (d+)" rating to a "hold (c-)" rating in a report on Monday, April 13th. Wall Street Zen raised shares of 908 Devices from a "hold" rating to a "buy" rating in a report on Saturday, March 14th. One analyst has rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $12.00.

About 908 Devices

908 Devices Inc NASDAQ: MASS is a developer and manufacturer of portable analytical instruments designed to deliver rapid chemical detection in field and laboratory environments. The company's core focus lies in miniaturizing high-performance mass spectrometry and ion mobility spectrometry technologies, enabling users to perform on-site analysis that traditionally required benchtop equipment.

Key products in 908 Devices' portfolio include the MX908, a handheld high-resolution mass spectrometer capable of detecting and identifying a broad range of chemicals and explosives; the M908 portable mass spectrometer for laboratory or mobile units; and the ZipChip capillary electrophoresis system for high-throughput, microfluidic separations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.